Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 3Other hematologic neoplasm 1

Conditions

Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma 2Immunoblastic Lymphadenopathy 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic, T-Cell 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 9mogamulizumab 6Biopsy 6fludarabine 5fludarabine phosphate 4Specimen Handling 4Immunoglobulin G 4Disulfides 4Brentuximab Vedotin 4ruxolitinib 3romidepsin 3pembrolizumab 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Etoposide 3Busulfan 3hypericin 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Nivolumab 2Melphalan 2Depsipeptides 2tofacitinib 1thymoglobulin 1tazemetostat 1talimogene laherparepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × romidepsin × 1 year × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡